NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT01164202 2022-03-18
SATURNE
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT00787787 2017-06-01
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
University of Washington
Phase 2 Terminated
NCT00524316 2017-05-09
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00361309 2014-03-18
SU011248 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT01215565 2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT00699374 2013-01-14
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Pfizer
Phase 3 Terminated
NCT00514228 2012-06-26
Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Swiss Cancer Institute
Phase 2 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn